Tango Therapeutics TNGX 深 滬
等待開盤 11-08 09:30:00 美东时间
7.40
-0.610
-7.62%
華盛通- 最 高8.13
- 今 開7.90
- 成交量 89.38万股
- 最 低 7.37
- 昨 收 8.01
- 總市值 7.99亿
- 52周最高 9.70
- 市盈率 靜 --
- 換手率 0.83%
- 52周最低 1.03
- 委 比 18.09%
- 總股本 1.08亿
- 歷史最高 18.84
- 量 比 0.70
- 振 幅 9.49%
- 歷史最低 1.03
- 每 手 1
- 風險率 2.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
Tango Therapeutics reported strong financial results for Q3 2025, with $225 million in gross proceeds extending their cash runway into 2028. Key updates include positive clinical data for vopimetostat in MTAP-del pancreatic cancer (mPFS 7.2 months) and plans for a pivotal trial in 2026. Combination studies with RAS(ON) inhibitors are progressing, and 49% ORR and 9.1 months mPFS were observed in a histology-selective cohort. The company also secur...
11-04 14:00
美股大行评级 | 升至45美元！英特尔获多家机构上调目标价；大摩上调拖拉机供应公司(TSCO)评级至"标配"，目标价升至60美元
今日重点评级关注：HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从10美元升至50美元；RBC Capital：维持Precision Drilling"跑赢大市"评级，目标价从110美元升至117美元
10-27 09:45
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $12
Guggenheim analyst Charles Zhu maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $10 to $12.
10-24 20:01
Tango Therapeutics Announces Major Stock Offering
The latest announcement is out from Tango Therapeutics ( ($TNGX) ). On October ...
10-24 18:48
Tango Therapeutics rises on $225M financing
Tango Therapeutics (NASDAQ:TNGX) has priced an underwritten offering of 21,023,337 shares of common stock and pre-funded warrants to purchase up to 3,226,458 shares. The common stock is priced at $8.6...
10-23 19:33
Tango Therapeutics Announces Preliminary Financial Results
Tango Therapeutics ( ($TNGX) ) has provided an announcement. On October 23, 202...
10-23 19:29
Tango Therapeutics Announces $225M Financing; Prices $210M Offering Of 21M Shares At $8.66 And 3.2M Pre-Funded Warrants At $8.659
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten
10-23 19:23
Tango Therapeutics' New Drug Doubles Response Rates in Deadly Pancreatic Cancer Trial
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced positive data from its ongoing
10-23 19:06
Tango Therapeutics Announces $225 Million Financing
<p>Tango Therapeutics, a clinical-stage biotechnology company focused on precision cancer medicines, priced an underwritten offering of 21,023,337 shares of common stock and pre-funded warrants, raising approximately $210 million. The offering price for each share and warrant was $8.66 and $8.659, respectively. The offering is expected to close on October 24, 2025. Notable investors include Farallon Capital Management, TCGX, Balyasny Asset Manage...
10-23 11:20
